We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Advanced Melanoma

Journal Scan / Research · August 31, 2020

Histopathological Features of pCR Predict RFS Following Neoadjuvant Targeted Therapy for Metastatic Melanoma

Annals of Oncology


Additional Info

Annals of Oncology
Histopathological Features of Complete Pathological Response Predict Recurrence-Free Survival Following Neoadjuvant Targeted Therapy for Metastatic Melanoma
Ann. Oncol 2020 Jul 30;[EPub Ahead of Print], MT Tetzlaff, C Adhikari, S Lo, RV Rawson, RN Amaria, AM Menzies, JS Wilmott, PM Ferguson, MI Ross, AJ Spillane, KA Vu, J Ma, J Ning, L Haydu, RPM Saw, JA Wargo, HA Tawbi, JE Gershenwald, GV Long, MA Davies, RA Scolyer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading